FIG. 1



Binding of GenPharm Mabs to αVβ3
c7E3
C371A
C372A
O.D. 490nm
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
0.001
0.010
0.100
1.000
µg/ml Mab

FIG. 2



ReoPro - anti-$\alpha_v\beta_5$ EC_{50} = 84 nM
ReoPro + anti-$\alpha_v\beta_5$ EC_{50} = 10 nM
Gen095 + anti-$\alpha_v\beta_5$ EC_{50} = 16 nM
Gen095 - anti-$\alpha_v\beta_5$ EC_{50} = 14 nM
C372A - anti-$\alpha_v\beta_5$
C372A + anti-$\alpha_v\beta_5$
% of Maximal M21 Cell Binding
125
100
75
50
25
0
10^{-2}
10^{-1}
10^{0}
10^{1}
10^{2}
10^{3}
10^{4}
[antibody] nM

FIG. 3



Adhesion of human Breast Carcinoma MDAMB435L2 cells to vitronectin
Gen O95
ReoPro
Absorbance 490 nm
1.2
1.0
0.8
0.6
0.4
0.2
0.0
0
1
2
3
4
5
6
7
8
20
120
µg/mL Mab

FIG. 4A



Binding of αVβ3 to GenO95 Plate in presence of 50 mM EDTA (no Ca++) or with Ca++ alone
αVβ3 + EDTA
αVβ3 + Ca
OD 490
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
0.001
0.010
0.100
1.000
10.000
100.000
[αVβ3, μg/mL]

FIG. 4B



Binding of αVβ3 to C372A Plate in presence of 50 mM EDTA (no Ca++) or with Ca++ alone
αVβ3 + EDTA
αVβ3 + Ca
OD 490
1.0
0.8
0.6
0.4
0.2
0.0
0.001
0.010
0.100
1.000
10.000
100.000
[αVβ3, μg/mL]

FIG. 4C



Binding of αVβ3 to c7E3 IgG
Plate in presence of 50 mM
EDTA (no Ca++) or with Ca++
alone
OD
490
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0.001
0.010
0.100
1.000
10.000
100.000
[αVβ3, μg/mL]
αVβ3 + EDTA
αVβ3 + Ca

FIG. 4D



Binding of αVβ3 to LM609 IgG
Plate in presence of 50 mM
EDTA (no Ca++) or with Ca++
alone
OD
490
4.0
3.6
3.2
2.8
2.4
2.0
1.6
1.2
0.8
0.4
0.0
0.001
0.010
0.100
1.000
10.000
100.000
[αVβ3, μg/mL]
αVβ3 + EDTA
αVβ3 + Ca

FIG. 4E



Binding of αVβ5 to GenO95 IgG Plate in presence of 50 mM EDTA (no Ca++) or with Ca++ alone
OD 490
1.0
0.8
0.6
0.4
0.2
0.0
0.001
0.010
0.100
1.000
10.000
100.000
[αVβ5, μg/mL]
αVβ5 + Ca
αVβ5 + EDTA

FIG. 4F



Binding of αVβ5 to C372 IgG Plate in presence of 50 mM EDTA (no Ca++) or with Ca++ alone
OD 490
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
0.001
0.010
0.100
1.000
10.000
100.000
[αVβ5, μg/mL]
αVβ5 + Ca
αVβ5 + EDTA

FIG. 4G



Binding of αVβ5 to c7E3 IgG Plate in presence of 50 mM EDTA (no Ca++) or with Ca++ alone
αVβ5 + Ca
αVβ5 + EDTA
OD 490
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
0.001 0.010 0.100 1.000 10.000 100.000
[αVβ5, μg/mL]

FIG. 5A



GenO.95 binding on $\alpha_V\beta_3$ (n=6)
125
100
75
50
25
0
-25
% Max binding
Kd = 2.1 ± 1.33 x 10^{-10} M
(0.03 ± 0.020 µg/ml)
-5
0
5
10
15
20
25
GenO.95 concentration (µg/ml)

FIG. 5B



ReoPro binding on $\alpha_V\beta_3$ (n=6)
125
100
75
50
25
0
-25
% Max binding
Kd = 2.5 ± 1.46 x 10^{-10} M
(0.01 ± 0.07 µg/ml)
-5
0
5
10
15
20
25
ReoPro concentration (µg/ml)

FIG. 6A



GenO.95 binding on $\alpha_v\beta_5$ (n=6)
125
100
75
50
25
0
-25
% Max binding
-5
0
5
10
15
20
25
GenO.95 concentration (µg/ml)
Kd = 2.5 ± 1.04 x 10^{-11} M
(0.004 ± 0.0016 µg/ml)

FIG. 6B



ReoPro binding on $\alpha_v\beta_5$ (n=4)
125
100
75
50
25
0
-25
% Max binding
0
5
10
15
20
25
ReoPro concentration (µg/ml)

FIG. 7A




FIG. 7B




FIG. 7C




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 9




FIG. 10



Number of capillary sprouts per 50 beads
0
2
4
6
8
10
12
14
Control
M-IgG (20µg/ml)
H-IgG (20µg/ml)
GenO95 (10µg/ml)
GenO95 (20µg/ml)
GenO95 (40µg/ml)
LM609 (10µg/ml)
PIF6 (10µg/ml)
LM-PIF6 (10µg/ml)

FIG. 11



Number of capillary sprouts per 50 beads
0
10
20
30
40
50
Control
m-IgG (20µg/ml)
H-IgG (20µg/ml)
GenO95 (10µg/ml)
GenO95 (20µg/ml)
GenO95 (40µg/ml)
LM609 (10µg/ml)
PIF6 (10µg/ml)
LM-PIF6 (10µg/ml)

FIG. 12A




FIG. 12B




FIG. 12C




FIG. 12D




FIG. 12E




FIG. 12F




FIG. 12G




FIG. 12H




FIG. 12I




FIG. 13



Type I Collagen
Fibronectin
Gelatin
Fibrin
Fibrinogen
Vitronectin
Adhesion % Control
120
100
80
60
40
20
0
0.0
2.5
5.0
7.5
10.0
12.5
Gen095 (µg/ml)

FIG. 14



Type I Collagen
Fibronectin
Fibrin
Gelatin
Fibrinogen
Vitronectin
Adhesion % Control
120
100
80
60
40
20
0
0.0
2.5
5.0
7.5
10.0
12.5
Gen095 (µg/ml)

FIG. 15



Adhesion % Control
120
100
80
60
40
20
0
0.0
2.5
5.0
7.5
10.0
12.5
Gen095 (µg/ml)

FIG. 16A FIG. 16B FIG. 16C




FIG. 16D




FIG. 17



Migration %
Control
150
100
50
0
BSA
Mouse IgG
Human IgG
LM609
PIF6
LM609-PIF6
Gen095

FIG. 18A




FIG. 18B




FIG. 18C FIG. 18D FIG. 18E




FIG. 19A




FIG. 19B





FIG. 19C FIG. 19D FIG. 19E






FIG. 20D




FIG. 20C




FIG. 20B





FIG. 20A

FIG. 20E



Vn (2μg/ml)Coated	+	+	+	+	+	+	+	+	+	+	+
Gen095 (μg/ml)	-	0	5	10	20	40	0	0	0	0	0
bFGF (20 ng/ml)	-	+	+	+	+	+	+	+	+	+	+
Human IgG (20μg/ml)	-	-	-	-	-	-	+	-	-	-	-
Mouse IgG (20μg/ml)	-	-	-	-	-	-	-	+	-	-	-
LM609 (10μg/ml)	-	-	-	-	-	-	-	-	+	-	+
PIF6 (10μg/ml)	-	-	-	-	-	-	-	-	-	+	+

FIG. 21A



FIG. 21B




FIG. 21C




FIG. 21D

